Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic
  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Advances IGC-AD1 Research to Potentially Deliver ‘Breakthrough Treatment’ in Alzheimer’s Disease

IGC Pharma (NYSE American: IGC), an AI-powered, clinical-stage biotechnology company, is announcing the advancement of its proprietary formulation, IGC-AD1, an orally administered medication with a strong safety profile, toward clinical trials as a potential anti-amyloid disease-modifying treatment for Alzheimer’s disease. According to the announcement, IGC Pharma is positioned to make a significant contribution with IGC-AD1 following the FDA’s 2023 approval of Donanemab (Eli Lily) and Lecanemab (Eisai and Biogen), two groundbreaking anti-amyloid drugs. Amyloid-targeted therapies are known to slow Alzheimer’s progression and improve cognitive function. The announcement noted that while these approvals have been a significant milestone in enhancing disease treatment, there is still an increasing demand for safe and effective treatments.

“As we continue our ongoing Phase 2 clinical trials for treating agitation in Alzheimer’s dementia with IGC-AD1, we’re excited to advance our research into its potential as an anti-amyloid disease-modifying treatment… The initiation of disease-modifying investigational trials, expected in early 2025, will open a significant market opportunity for IGC Pharma,” stated Ram Mukunda, CEO of IGC Pharma. “By initiating new trials focused on IGC-AD1’s ability to modify amyloid plaque progression, we hope to position IGC Pharma to deliver a breakthrough treatment in Alzheimer’s disease, driving substantial value for our shareholders.”

To view the full press release, visit https://ibn.fm/HQzeO

About IGC Pharma Inc.

IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer’s disease and transforming patient care with fast-acting, safe, and effective solutions. The company’s portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer’s. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. The company’s lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 clinical trial for agitation in dementia associated with Alzheimer’s (clinicaltrials.gov, NCT05543681). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medication. Additionally, IGC Pharma’s AI models are designed to predict potential biomarkers for the early detection of Alzheimer’s, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, the company is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer’s and related conditions.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.